Targeted Cellular Therapy in Blood Cancers | CTL019 for Leukemia


Related Videos (117)

Hematologist-Oncologist David L. Porter, MD, presents on the pioneering use of CTL-019 (formerly CART-19) at Penn Medicine for adoptive immunotherapy in patients with relapsed or chemotherapy-refractory chronic lymphocytic leukemias (CLL) and acute lymphoblastic leukemias (ALL). To date, CTL-019 is the only therapy to bring about sustained remission for these leukemias in adult patients with refractory disease.


Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®